Founded in 1967 and is headquartered in Madison, New Jersey, Quest Diagnostics Incorporated (NYSE: DGX) provides diagnostic testing, information, and services in the United States and internationally. In addition, Quest Diagnostics provides central laboratory testing services in connection with clinical research trials on new drugs, vaccines, and medical devices; and clinical testing to employers for the detection of employee use of drugs-of-abuse.
Quest Diagnostics, the world's leading provider of diagnostic testing, information and services, yesterday announced that the U.S. Food and Drug Administration (FDA) has granted a de novo classification petition to its STRATIFY JCV? Antibody ELISA testing service. STRATIFY JCV is the first blood test to be FDA market authorized for the qualitative detection of antibodies to the polyomavirus JC virus (JCV) for stratifying risk for progressive multifocal leukoencephalopathy (PML), an infrequent but serious brain infection, in patients with multiple sclerosis (MS) receiving TYSABRI® (natalizumab), a highly effective therapy for relapsing forms of MS.
Read full article at : http://doubleinstocks.com/20073/stock-alerts/dgx-ego-gblhf-tdw-pgh-stock...
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DoubleInStocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. The views expressed in any article, reports, writings are not necessarily the views of Crown Equity Holdings, Inc. its officers, directors, staff, contractors or employees. They do not represent the views or opinions of this site. Views expressed in articles are those of the author alone. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. (Read more at: http://doubleinstocks.com/disclaimer) Release of Liability: Through use of this website viewing or using, you agree to hold DoubleInStocks.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings, Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings, Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings, Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings, Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.